Amneal Pharmaceuticals (AMRX) Share-based Compensation (2017 - 2026)

Amneal Pharmaceuticals has reported Share-based Compensation for 10 years, with the latest figure at $176000.0 in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 6.88% year-over-year to $176000.0 in Q2 2026; TTM through Jun 2026 was $54.6 million, a 51.05% increase from a year earlier, with the FY2025 full-year figure at $32.0 million, up 15.07% from the prior year.
• Share-based Compensation was $176000.0 for Q2 2026 at Amneal Pharmaceuticals, down from $44.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $44.3 million in Q1 2026, with the low at $176000.0 in Q2 2026.
• Average Share-based Compensation over 5 years is $9.0 million, with a median of $7.2 million recorded in 2024.
• The largest YoY upside for Share-based Compensation was 200.04% in 2025 against a maximum downside of 96.97% in 2025.
• Over 5 years, Share-based Compensation stood at $7.8 million in 2022, then fell by 23.71% to $6.0 million in 2023, then grew by 20.69% to $7.2 million in 2024, then rose by 13.76% to $8.2 million in 2025, then slumped by 97.85% to $176000.0 in 2026.
• The last three Share-based Compensation figures came in at $176000.0 (Q2 2026), $44.3 million (Q1 2026), and $8.2 million (Q4 2025), per Business Quant data.